Eupraxia Pharmaceuticals (EPRX) Convertible Debt (2022 - 2024)

Eupraxia Pharmaceuticals (EPRX) has reported Convertible Debt for 3 consecutive years, with $4.5 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Convertible Debt changed N/A year-over-year to $4.5 million; the TTM figure through Jun 2024 stood at $4.5 million (changed N/A YoY), while the FY2023 annual figure was $10.3 million, up 18.23% from the prior year.
• Convertible Debt eased to $4.5 million in Q2 2024 per EPRX's latest filing, from $9.5 million in the prior quarter.
• Across five years, Convertible Debt topped out at $10.3 million in Q4 2023 and bottomed at $4.5 million in Q2 2024.
• Historically, Convertible Debt has averaged $8.3 million across 3 years, with a median of $9.1 million in 2022.
• On a YoY basis, Convertible Debt climbed as much as 18.23% in 2023 and fell as far as 18.23% in 2023.
• Eupraxia Pharmaceuticals' Convertible Debt stood at $8.7 million in 2022, then advanced by 18.23% to $10.3 million in 2023, then tumbled by 56.15% to $4.5 million in 2024.
• Business Quant data shows EPRX's Convertible Debt at $4.5 million in Q2 2024, $9.5 million in Q1 2024, and $10.3 million in Q4 2023.